Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 22 hours agoScore90
Body
NSABP B-42 (15-year data): #ESMO26
Extended letrozole reduces distant recurrence, but without a significant OS benefit.
🔹 Node-positive: 4.4% absolute benefit
🔹 Node-negative: 1.6% (not statistically significant)
@OncoAlert #BreastCancer #bcsm
867 views · 29 likes · 8 reposts · 1 reply
Source: Aya Mohamed | MSc, MD 🎗 · x.com